The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety - PubMed (original) (raw)

Comparative Study

. 2004 Nov;29(11):1971-9.

doi: 10.1038/sj.npp.1300540.

Affiliations

• PMID: 15305166
• DOI: 10.1038/sj.npp.1300540

Comparative Study

The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety

Chris S Busse et al. Neuropsychopharmacology. 2004 Nov.

Abstract

Previous reports have demonstrated the anxiolytic effect of the potent and systemically active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) in rodents. Here, we present evidence for the anxiolytic activity of a novel mGlu5 receptor antagonist, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP), in rats and compare its profile to the benzodiazepine receptor agonist diazepam. MTEP occupied mGlu5 receptors in a dose-dependent manner with essentially full receptor occupancy at the highest dose tested (10 mg/kg, i.p.). At doses appropriate for mGlu5 receptor-mediated effects, MTEP significantly reduced fear-potentiated startle and increased punished responding in a modified Geller-Seifter conflict model consistent with an anxiolytic-like profile. In both models, the magnitude of the anxiolytic-like response was similar to that seen with diazepam. In contrast, MTEP decreased unpunished responding to a lesser extent than diazepam and had no effect on rotarod performance when administered either alone or in combination with ethanol. Repeated dosing with MTEP in this model eliminated the increase in punished responding observed with acute dosing. The present results suggest that mGlu5 receptor antagonists lack the side effects seen with benzodiazepines, such as sedation and ethanol interaction, and provide insight into a possible role for mGlu5 receptor antagonists in the modulation of mood disorders.

PubMed Disclaimer

Similar articles

• Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats.
  Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wisłowska A, Płaźnik A, Bespalov AY, Danysz W. Pietraszek M, et al. Eur J Pharmacol. 2005 May 2;514(1):25-34. doi: 10.1016/j.ejphar.2005.03.028. Epub 2005 Apr 19. Eur J Pharmacol. 2005. PMID: 15878321
• Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling.
  Klodzinska A, Tatarczyńska E, Chojnacka-Wójcik E, Nowak G, Cosford ND, Pilc A. Klodzinska A, et al. Neuropharmacology. 2004 Sep;47(3):342-50. doi: 10.1016/j.neuropharm.2004.04.013. Neuropharmacology. 2004. PMID: 15275823
• [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization.
  Anderson JJ, Rao SP, Rowe B, Giracello DR, Holtz G, Chapman DF, Tehrani L, Bradbury MJ, Cosford ND, Varney MA. Anderson JJ, et al. J Pharmacol Exp Ther. 2002 Dec;303(3):1044-51. doi: 10.1124/jpet.102.040618. J Pharmacol Exp Ther. 2002. PMID: 12438526
• Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP.
  Lea PM 4th, Faden AI. Lea PM 4th, et al. CNS Drug Rev. 2006 Summer;12(2):149-66. doi: 10.1111/j.1527-3458.2006.00149.x. CNS Drug Rev. 2006. PMID: 16958988 Free PMC article. Review.
• [18F]3-Fluoro-5-[(2-methyl-1,3-thiazol-4-yl)ethynyl]benzonitrile.
  The MICAD Research Team. The MICAD Research Team. 2006 Jul 12 [updated 2006 Jul 24]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2006 Jul 12 [updated 2006 Jul 24]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641339 Free Books & Documents. Review.

Cited by

• Control of Theta Oscillatory Activity Underlying Fear Expression by mGlu5 Receptors.
  Matulewicz P, Ramos-Prats A, Gómez-Santacana X, Llebaria A, Ferraguti F. Matulewicz P, et al. Cells. 2022 Nov 10;11(22):3555. doi: 10.3390/cells11223555. Cells. 2022. PMID: 36428984 Free PMC article.
• The metabotropic glutamate 5 receptor modulates extinction and reinstatement of methamphetamine-seeking in mice.
  Chesworth R, Brown RM, Kim JH, Lawrence AJ. Chesworth R, et al. PLoS One. 2013 Jul 4;8(7):e68371. doi: 10.1371/journal.pone.0068371. Print 2013. PLoS One. 2013. PMID: 23861896 Free PMC article.
• Inhibition of spontaneous recovery of fear by mGluR5 after prolonged extinction training.
  Mao SC, Chang CH, Wu CC, Orejarena MJ, Manzoni OJ, Gean PW. Mao SC, et al. PLoS One. 2013;8(3):e59580. doi: 10.1371/journal.pone.0059580. Epub 2013 Mar 21. PLoS One. 2013. PMID: 23555716 Free PMC article. Retracted.
• Inhibiting metabotropic glutamate receptor 5 after stroke restores brain function and connectivity.
  Hakon J, Quattromani MJ, Sjölund C, Talhada D, Kim B, Moyanova S, Mastroiacovo F, Di Menna L, Olsson R, Englund E, Nicoletti F, Ruscher K, Bauer AQ, Wieloch T. Hakon J, et al. Brain. 2024 Jan 4;147(1):186-200. doi: 10.1093/brain/awad293. Brain. 2024. PMID: 37656990 Free PMC article.
• Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson's Disease.
  Epping-Jordan MP, Girard F, Bessis AS, Mutel V, Boléa C, Derouet F, Bessif A, Mingard B, Barbier S, Paradis JS, Rocher JP, Lütjens R, Kalinichev M, Poli S. Epping-Jordan MP, et al. Cells. 2023 Mar 24;12(7):1004. doi: 10.3390/cells12071004. Cells. 2023. PMID: 37048075 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information